Association of CACNA1C gene genetic polymorphism with the susceptibility as well as prognosis for chronic spontaneous urticaria.
10.11817/j.issn.1672-7347.2018.09.001
- Author:
Jinjie YAN
1
,
2
;
Qinglin LI
1
,
2
;
Yuxue LUO
1
,
2
;
Siyu YAN
1
,
3
;
Yijing HE
1
,
3
;
Xiang CHEN
1
,
3
Author Information
1. Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008
2. 2012 Grade Five Years of Clinical Medicine, Xiangya School of Medicine, Central South University, Changsha 410078, China.
3. Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha 410008, China.
- Publication Type:Journal Article
- MeSH:
Calcium Channels, L-Type;
genetics;
Chronic Disease;
Genetic Predisposition to Disease;
Histamine H1 Antagonists, Non-Sedating;
therapeutic use;
Humans;
Loratadine;
analogs & derivatives;
therapeutic use;
Polymorphism, Single Nucleotide;
Prognosis;
Retrospective Studies;
Urticaria;
drug therapy;
genetics
- From:
Journal of Central South University(Medical Sciences)
2018;43(9):929-936
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the relationship between single nucleotide polymorphisms (SNPs) of CACNA1C (SNPs rs58619945, rs7316246 and rs216008) and susceptibility of chronic spontaneous urticaria (CSU) as well as the curative effect of non-sedating antihistamine drugs.
Methods: Peripheral blood were extracted from 191 CSU patients to collect DNA. Urticaria Activity Score 7 (UAS7) and Dermatology Life Quality Index (DLQI) changes were collected from these patients with different non-sedating antihistamine drugs. PubMed retrieval system was used to select the 3 SNPs (rs58619945, rs7316246 and rs216008) of CACNA1C. Susceptibility of CSU and curative effect of non-sedating antihistamine drugs (desloratadine, mizolastine, fisofenadine) in 189 CSU patients and 105 controls with different SNPs were compared with Chi-squared test. Data of 105 southern Chinese controls were extracted from the 1 000 genome database.
Results: Frequency of rs58619945 G allele in the CSU patients was significantly higher than that in the controls [OR(95%CI)=0.660(0.470-0.925), P=0.016]. However, there was no significant differences in rs7316246 and rs216008 between the CSU patients and the controls. Meanwhile there was no significant difference in general curative effect of the 3 drugs in the 3 SNPs (rs58619945: OR=0.843, P=0.454; rs7316246: OR=2.103, P=0.102; rs216008: OR=0.237, P=0.363). There was significant difference in different alleles of rs216008 in the patients administered by desloratadine [OR(95%CI)=0.480(0.247-0.933), P=0.029]. No difference was shown in the 3 SNPs in patients administered by mizolastine.
Conclusion: The rs58619945 A/G might be related to susceptibility of CSU, and the rs216008 mutation might affect drug response of desloratadine.
